Feasibility of localized immunosuppression: 2. PLA microspheres for the sustained local delivery of a soft immunosuppressant

Pharmazie

Volumn 65, Issue 6, 2010, Pages 429-435

  Pinto, E ^a   Zhang, B ^a   Song, S ^a   Bodor, N ^a   Buchwald, P ^b   Hochhaus, Guenther ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMULSIFYING AGENT; LOTEPREDNOL ETABONATE; MICROSPHERE; POLY(DEXTRO,LEVO LACTIC) ACID; POLY(DEXTRO,LEVO LACTIC) GLYCOLIC ACID; UNCLASSIFIED DRUG; ANDROSTANE DERIVATIVE; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; EXCIPIENT; IMMUNOSUPPRESSIVE AGENT; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID POLYGLYCOLIC ACID COPOLYMER; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; SOLVENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL LINE; CELL TRANSPLANTATION; CELL VIABILITY; COMPUTER MODEL; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG EFFECT; DRUG SYNTHESIS; EMULSION; FEASIBILITY STUDY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INSULINOMA; NONHUMAN; OSMOTIC MINIPUMP; PANCREAS ISLET; PARTICLE SIZE; RAT; SLOW DRUG RELEASE; SUSTAINED DRUG RELEASE; ALGORITHM; ANIMAL; CELL SURVIVAL; CHEMISTRY; DELAYED RELEASE FORMULATION; EXPERIMENTAL DIABETES MELLITUS; HUMAN; IMMUNOLOGY; PANCREAS ISLET TRANSPLANTATION; SCANNING ELECTRON MICROSCOPY; SOLUBILITY; X RAY DIFFRACTION;

ALGORITHMS; ANDROSTADIENES; ANIMALS; CELL LINE; CELL SURVIVAL; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, EXPERIMENTAL; EXCIPIENTS; FEASIBILITY STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDICATORS AND REAGENTS; ISLETS OF LANGERHANS TRANSPLANTATION; LACTIC ACID; MICROSCOPY, ELECTRON, SCANNING; MICROSPHERES; PARTICLE SIZE; POLYGLYCOLIC ACID; RATS; SOLUBILITY; SOLVENTS; X-RAY DIFFRACTION;

EID: 77955296828     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2010.0033R     Document Type: Article

References (32)

1. Bala I, Hariharan S, Kumar MN (2004) PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst 21: 387-422.
2. Bocca N, Pileggi A, Molano RD, Marzorati S, Wu W, Bodor N, Ricordi C, Buchwald P (2008) Soft corticosteroids for local immunosuppression: exploring the possibility for the use of loteprednol etabonate in islet transplantation. Pharmazie 63: 226-232.
3. Bodor N, Buchwald P (2000) Soft drug design: general principles and recent applications. Med Res Rev 20: 58-101.
4. Bodor N, Buchwald P (2006) Corticosteroid design for the treatment of asthma: structural insights and the therapeutic potential of soft corticosteroids. Curr Pharm Des 12: 3241-3260.
5. Bodor N, Wu WM, Murakami T, Engel S (1995) Soft drugs. 19. Pharmacokinetics, metabolism and excretion of a novel soft corticosteroid, loteprednol etabonate, in rats. Pharm Res 12: 875-879.
6. Brem H, Gabikian P (2001) Biodegradable polymer implants to treat brain tumors. J Control Release 74: 63-67.
7. Brown JH, Douglas AF, Murphy BG, Hill CM, McNamee PT, Nelson WE, Doherty CC (1998) Treatment of renal failure in idiopathic membranous nephropathy with azathioprine and prednisolone. Nephrol DialTransplant 13: 443-448.
8. Buchwald P (2009) FEM-based oxygen consumption and cell viability models for avascular pancreatic islets. Theor Biol Med Model 6: art. 5.
9. Buchwald P, Bodor N (2004) Soft glucocorticoid design: structural elements and physicochemical parameters determining receptor-binding affinity. Pharmazie 59: 396-404.
10. Buchwald P, Bocca N, Marzorati S, Hochhaus G, Bodor N, Stabler C, Kenyon NS, Inverardi L, Molano RD, Ricordi C, Pileggi A (2010) Feasibility of localized immunosupression: 1. Explatory studies with glucocorticoids in a biohybrid device designed for cell transplantation. Pharmazie 65: XXX-XXX.(doi: 10.1691/ph. 2010.0525R).
11. Druzgala P, Hochhaus G, Bodor N (1991) Soft drugs-10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate. J Steroid Biochem Mol Biol 38: 149-154.
12. Dunne M, Corrigan I, Ramtoola Z (2000) Influence of particle size and dissolution conditions on the degradation properties of polylactide-coglycolide particles. Biomaterials 21: 1659-1668.
13. Fort A, Fort N, Ricordi C, Stabler CL (2008) Biohybrid devices and encapsulation technologies for engineering a bioartificial pancreas. Cell Transplant. 17: 997-1003.
14. Gruber SA, Hughes SE, Xiao S, Perera S, Jayasankar V, Rosario AD, Singh J (1997) Pharmacokinetics and pharmacodynamics of 15-deoxyspergualin in a canine renal allograft model of local immunosuppression. J Surg Res 71: 137-144.
15. Harbaugh RE, Saunders RL, Reeder RF (1988) Use of implantable pumps for central nervous system drug infusions to treat neurological disease. Neurosurgery 23: 693-698.
16. Hickey T, Kreutzer D, Burgess DJ, Moussy F (2002) Dexamethasone/PLGA microspheres for continuous delivery of an anti-inflammatory drug for implantable medical devices. Biomaterials 23: 1649-1656.
17. Hyon SH (2000) Biodegradable poly (lactic acid) microspheres for drug delivery systems. Yonsei Med J 41: 720-734.
18. Ignatius AA, Claes LE (1996) In vitro biocompatibility of bioresorbable polymers: poly(l, dl-lactide) and poly(l-lactide-co-glycolide) Biomaterials 17: 831-839.
19. Juang JH, Bonner-Weir S, Ogawa Y, Vacanti JP, Weir GC (1996) Outcome of subcutaneous islet transplantation improved by polymer device.Transplantation 61: 1557-1561.
20. Kompella UB, Bandi N, Ayalasomayajula SP (2003) Subconjunctival Nanoand Microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest Ophthalmol Vis Sci 44: 1192-1201.
21. Liggins RT, Burt HM (2004) Paclitaxel-loaded poly(l-lactic acid) microspheres 3: blending low and high molecular weight polymers to control morphology and drug release. Int J Pharm 282: 61-71.
22. Murillo M, Gamazo C, Goni M, Irache J, Blanco-Prieto M (2002) Development of microparticles prepared by spray-drying as a vaccine delivery system against brucellosis. Int J Pharm 242: 341-344.
23. Narang AS, Mahato RI (2006) Biological and biomaterial approaches for improved islet transplantation. Pharmacol Rev 58: 194-243.
24. Perales MA, Ishill N, Lomazow WA, Weinstock DM, Papadopoulos EB, Dastigir H, Chiu M, Boulad F, Castro-Malaspina HR, Heller G, Jakubowski AA, O'Reilly RJ, Small TN, Young JW, Kernan NA (2007) Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease. Bone Marrow Transplant 40: 481-486.
25. Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, Neuhaus P (1994) Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplantation 58: 170-178.
26. Ranta F, Avram D, Berchtold S, Düfer M, Drews G, Lang F, Ullrich S (2006) Dexamethasone induces cell death in insulin-secreting cells, an effect reversed by exendin-4. Diabetes 55: 1380-1390.
27. Rhee K, Bresnahan W, Hirai A, Hirai M, Thompson EA (1995) c-Myc and cyclin D3 (CcnD3) genes are independent targets for glucocorticoid inhibition of lymphoid cell proliferation. Cancer Res 55: 4188-4195.
28. Sakurai T, Satake A, Nagata N, Gu Y, Hiura A, Doo-Hoon K, Hori H, Tabata Y, Sumi S, Inoue K (2003) The development of new immunoisolatory devices possessing the ability to induce neovascularization. Cell Transplant 12: 527-535.
29. Steffen M, Scherdin U, Duvigneau C, Hölzel F (1988) Glucocorticoid-induced alterations of morphology and growth of fibrosarcoma cells derived from 7,12-dimethylbenz(a)anthracene rat mammary tumor. Cancer Res 48: 7212-7218.
30. Tchekneva E, Serafin WE (1994) Kirsten sarcoma virus-immortalized mast cell lines. Reversible inhibition of growth by dexamethasone and evidence for the presence of an autocrine growth factor. J Immunol 152: 5912-5921.
31. Weinberg BD, Blanco E, Blanc E, Ga JM (2007) Polymer implants for intratumoral drug delivery and cancer therapy. J Pharm Sci 97: 1681-1702.
32. Zhang P, L Chen, Gu W, Xu Z, Gao Y, Li Y (2007) In vitro and in vivo evaluation of donepezil-sustained release microparticles for the treatment of Alzheimer's disease. Biomaterials 28: 1882-1888.